Azenta, Inc. AZTA

As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the drug development inputs & services industry, including Azenta (NASDAQ:AZTA) and its peers.

Azenta, Inc. (Nasdaq: AZTA) today announced that it has received repayment in full, prior to maturity, of the $35 million secured vendor loan extended in connection with the previously announced sale of B Medical Systems S.à r.l. to Thelema S.à r.l.

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have not only realized strong financial performance but also propelled the broader industry’s returns as healthcare stocks have gained 22.1% over the past six months while the S&P 500 was up 12.1%.

Check out the companies making headlines yesterday:

Shares of life sciences company Azenta (NASDAQ:AZTA) fell 9.1% in the afternoon session after the company announced, in a regulatory filing, that President and CEO John Marotta resigned from his executive roles and board seat, with current director Dr. Martin Madaus appointed as interim President and CEO.

Azenta, Inc. (Nasdaq: AZTA) ("Azenta" or "the Company") today announced that current member of the Board of Directors (the "Board") Dr. Martin Madaus has been appointed interim President and CEO, and that John Marotta has resigned as an executive officer and director of the Company.

The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, upbeat results, or supportive macro developments. As such, investors are taking notice and bidding up shares.

Azenta’s second quarter showed strong momentum, with results surpassing Wall Street’s expectations for both revenue and earnings. Management attributed this outperformance to robust growth in its biorepositories and consumables and instruments (C&I) segments, which are recurring revenue businesses, alongside improved execution in Multiomics, particularly in Europe and China. CEO John Marotta highlighted, “Revenue exceeded our outlook, profitability improved sequentially and Multiomics delivered

Azenta, Inc. recently reported third-quarter 2026 results showing revenue of US$161.18 million versus US$143.86 million a year earlier, swung to a quarterly net income of US$2.46 million from a net loss, modestly raised full-year revenue guidance to US$613–US$618 million, and completed a US$50 million repurchase of 2,300,000 shares. While the company still reported a higher net loss of US$173.77 million over the first nine months of fiscal 2026 than a year earlier, the combination of...

Conestoga Capital Advisors, an asset management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The letter reports a positive market shift towards Small Caps, with the Russell 2000 Index achieving its best first half since 1991 and the Russell 2000 Growth Index up 25.7% in Q2, fueled by AI enthusiasm […]

Strong multi-omics performance in Europe and China offsets capital equipment softness, while company completes B Medical divestiture and boosts shareholder returns.

Moby summary of Azenta, Inc.'s Q3 2026 earnings call

Life sciences company Azenta (NASDAQ:AZTA) announced better-than-expected revenue in Q2 CY2026, with sales up 12% year on year to $161.2 million. Its non-GAAP profit of $0.16 per share was 60% above analysts’ consensus estimates.

Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the third quarter ended June 30, 2026.